Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platelet alpha granules are the most abundant type of secretory granule in platelets, comprising about 50–80 per cell and accounting for approximately 10% of platelet volume[5][6][7]. They are membrane-bound organelles, 200–500 nm in diameter, containing a wide array of proteins, including growth factors (e.g., platelet-derived growth factor, vascular endothelial growth factor), clotting factors (e.g., fibrinogen, factor V, von Willebrand factor), chemokines (e.g., platelet factor 4, interleukin-8), adhesion molecules (e.g., P-selectin, fibronectin), and complement proteins[1][4][5][6][7]. Upon platelet activation, they release their granular contents to mediate blood coagulation, promote wound healing, modulate inflammation, and support angiogenesis. Dysfunction or deficiency of alpha granules, such as in gray platelet syndrome, leads to bleeding disorders and dysregulated hemostatic response[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet alpha granule (α-granule).